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Abstract
Background: Erlotinib is approved for the first line treatment of epidermal growth factor receptor (EGFR) mutation-
positive non-small cell lung cancer. Since the number of prospective studies in Caucasian patients treated in routine
clinical setting is limited we conducted a multicenter, phase IV clinical trial to determine the efficacy and safety of
erlotinib and to demonstrate the feasibility of the validated standardized companion diagnostic method of EGFR
mutation detection.
Methods: 651 chemonaive, cytologically or histologically verified advanced stage lung adenocarcinoma patients from
Hungary, Turkey and Latvia were screened for exon19 microdeletions and exon21 L858R EGFR mutations using the
companion diagnostic EGFR test. EGFR mutation-positive, locally advanced or metastatic lung adenocarcinoma patients
received as first line treatment erlotinib at 150 mg/day. The primary endpoint was progression-free survival (PFS).
Results: 62 EGFR mutation-positive patients (9.5% of screened) were included in the safety/intent-to-treat cohort.
Median PFS was 12.8 months (95%CI, 9.9–15.8), objective response rate and one-year survival was 66.1% and 82.5%,
respectively. Most frequent treatment related adverse events were diarrhoea and rash. Eastern Oncology Cooperative
Group Performance Status (ECOG PS), smoking status and M1a/M1b disease stage were significant prognosticators of
PFS (p = 0.017, p = 0.045 and p = 0.002, respectively). There was no significant difference in PFS between the subgroups
stratified by gender, age or exon19 vs exon21 mutation.
Conclusions: Our study confirmed the efficacy and safety of first line erlotinib monotherapy in Caucasian patients with
locally advanced or metastatic lung adenocarcinoma carrying activating EGFR mutations based on the screening with
the approved companion diagnostic procedure.
Trial registration: ClinicalTrials.gov Identifier: NCT01609543.
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Background
Lung cancer is the leading cause of cancer related mor-
tality worldwide [1]. In European lung adenocarcinoma
patients, the incidence of mutations of epidermal growth
factor receptor (EGFR) gene is between 5 to 10% [2–4].
Currently, three EGFR tyrosine kinase inhibitors (EGFR-
TKIs) including the first-generation, reversible TKI erlo-
tinib and gefitinib as well as the second-generation irre-
versible TKI afatinib are approved for the treatment of
patients with locally advanced or metastatic non-small
cell lung cancer (NSCLC) with EGFR activating muta-
tions [5]. For all three agents, the classic mutations of
L858R and exon 19 microdeletions can serve as positive
predictive biomarkers for response. Of note, a number
of additional so called rare EGFR mutations are also sen-
sitizing for EGFR-TKI therapy [4]. Erlotinib was demon-
strated to delay symptom progression, improve quality
of life and prolong survival as a first-line treatment when
compared to standard chemotherapy in patients with
exon 19 deletions or exon 21 (L858R) substitution muta-
tions of EGFR [6, 7]. In addition, erlotinib is also ap-
proved by the European Medicines Agency for the
treatment of patients with locally advanced or metastatic
NSCLC after failure of at least one prior chemotherapy
regimen (with no mutation analysis requirement) as well
as for switch maintenance treatment in patients with
locally advanced or metastatic NSCLC with EGFR ac-
tivating mutations and stable disease after first-line
chemotherapy [8].
EGFR mutations are associated with adenocarcinoma
histology and more often found in non-smokers. Especially
in Asian populations it is also more frequent in females
often associates with younger age [9]. These epidemio-
logical characteristics often influence the screening strategy.
The presence of KRAS mutations is in general mutually ex-
clusive with EGFR mutations and associates with the lack
of response to EGFR-TKIs [10–12].
Our multicenter, phase IV clinical trial was designed to
determine the efficacy and safety of erlotinib in routine
clinical practice and to demonstrate the feasibility of the
validated standardized companion diagnostic method of
EGFR mutation detection in Caucasian patients.
Patients and methods
Patients
The CEETAC (ClinicalTrials.gov Identifier: NCT01609543)
open-label, non-randomized, multicenter trial investigated
the efficacy and safety of first line erlotinib monotherapy in
routine clinical practice in 10 Hungarian, 5 Turkish and 2
Latvian clinical centers. 651 chemonaive, inoperable, ad-
vanced stage lung adenocarcinoma patients were screened
for EGFR mutation. Patients above the age of 18 years with
histologically or cytologically verified, inoperable, locally ad-
vanced, recurrent or metastatic lung adenocarcinoma
carrying an activating EGFR mutation (exon 19 microdele-
tions or exon 21 L858R point mutation) by using Cobas®
4800 EGFR Mutation Test at a designated central labora-
tory were included in the safety as well as in the intent-to-
treat cohort. 35 Hungarian, 15 Turkish and 12 Latvian
patients were eligible to participate in the study. All partici-
pants had to have an Eastern Cooperative Oncology Group
Performance Status (ECOG PS) between 0 and 2 and a life
expectancy of at least 12 weeks. All patients provided writ-
ten informed consent.
Mutation analysis
Formalin-fixed paraffin-embedded histological specimens
or stained cytological samples were assessed by patholo-
gists at light microscopy and tumour-rich areas were
macrodissected in sections and tumor to normal ratio was
determined. Cobas® DNA Sample Preparation Kit (Roche
Molecular Diagnostics) was then used to isolate DNA ac-
cording to the manufacturer’s instructions. The purity and
the concentration of the extracted DNA was determined
by Nanodrop 2000 (Thermo Fisher Scientific).
EGFR mutation analysis was carried out by Cobas®
EGFR Mutation Test (Roche Molecular Diagnostics), a
real-time PCR test for the qualitative detection of muta-
tions for which the safety and efficacy of erlotinib use
have been established: exon 19 deletions and exon 21
substitution L858R. The measurement was carried out
by Cobas® z 480 analyzer (Roche Molecular Diagnostics)
according to the manufacturer’s instructions using the
Cobas® 4800 System Microwell Plate and the primers,
probes and internal controls supplied with the kit.
Treatment and follow-up
Patients received erlotinib 150 mg/day orally until dis-
ease progression, withdrawal of consent or intolerable
adverse events. Examination of vital signs and routine
hematology was performed at every 28-day visit. Tumor
measurement and response grading was performed ac-
cording to institutional standard of care in line with
RECIST version 1.1 and with a maximum interval of
2 months. The primary endpoint was progression-free
survival (PFS), secondary endpoints were objective
tumor response, one-year survival and safety. PFS was
defined from the start of erlotinib treatment to the first
documented progression or death. Patients without pro-
gression were censored on the date of last evaluable
tumor assessment.
Statistical analysis
The association of gender, disease stage and smoking
with the exon19 and exon 21 subgroups was tested with
Fisher’s exact test. The difference in age and ECOG
score in these subgroups was tested by unpaired t-test
and by Chi-square test, respectively. PFS was estimated
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with the Kaplan-Meier method and described with the
median value and two-sided 95% confidence interval
(CI). Exploratory subgroup analyses of progression-free
survival were done with two-sided log-rank test and the
ratio of the median survival times including its 95% con-
fidence intervals are also reported. Multivariate analysis
was performed using the Cox-regression model to calcu-
late hazard ratios (HRs) and corresponding confidence




Out of the 651 screened patients, 62 with EGFR mutant
lung adenocarcinoma were enrolled from 17 participating
centers between March 2012 and January 2014 (Fig. 1A).
The last study visit was in January 2015 and data collec-
tion was closed in June 2015. The clinicopathological
characteristics dichotomized by exon 19 and 21 mutations
are summarized in Table 1. All but two patients were of
Caucasian origin. Mean age at the time of enrollment was
70.5 (range 28 to 86) years. There were 50 female and 12
male patients included. 6 patients (9.7%) were enrolled
with stage IIIb disease. Among the 56 stage IV cases, the
most frequently affected sites included 45 (80.4%) intra-
pulmonary, 19 (33.9%) bone and 7 (12.5%) liver metastasis
at the time of enrollment.
Treatment safety
During the study, 418 adverse events were recorded
from 56 patients. 88.2% of adverse events were grade I
and II. 159 non-serious adverse events (38%) and 15 ser-
ious adverse events (3.6%) were reported to have causal
relationship with erlotinib treatment. The list of non-
serious adverse events that occurred at a frequency of
5% or more is presented in Table 2. The most frequent
adverse events were diarrhoea and rash. Due to adverse
events dose modification was applied in fifteen patients
(24.1%) and erlotinib withdrawal was necessary in 5 (8.
1%) cases.
Treatment efficacy
Best overall response rate could be established for 56 pa-
tients (90.3% of the intent-to-treat population). One (1.8%)
complete and 36 (64.3%) partial responses as well as 18
stable (32.1%) disease were registered at response evalu-
ation resulting in a disease control rate of 98.2% (Fig. 1B).
Progressive disease (PD) as best tumor response was re-
ported in one patient (1.8%). 28 patients (45.2%) discontin-
ued treatment due to disease progression. 11 disease
progression related death occurred during the study. Ac-
cordingly, the number of events in the PFS analysis was 40.
The median follow-up time was 13.4 months (range 1.3 to
32.9). The progression-free survival was 12.8 months (95%
CI, 9.9–15.8; Fig. 2A).
Exploratory subgroup analysis for progression-free
survival
The progression-free survival in the various subgroups
was compared in order to identify the clinicopathologi-
cal variables that influence treatment outcome (Table 3).
There was no significant difference in PFS between the
subgroups stratified by gender, age (using the median
70 years of age as cutoff ) or mutation exon 19 or 21. In
contrast, ECOG PS was a significant predictor of
progression-free survival (p = 0.017; Fig. 2D). Never
smoker patients also had a significantly increased PFS
when compared to ever-smokers (15.4 versus 8.4 months;
p = 0.045; Fig. 2B). Furthermore, M1a disease at the time
of screening also associated with increased progression-
free survival when compared to M1b (18.9 versus 8.
5 months; p = 0.002; Fig. 2C). Finally, we performed
multivariate analyses using a multimodality Cox-
regression model adjusted for smoking, ECOG and M
stage. After multivariate PFS analyses, smoking (HR: 2.
07, CI: 1.04–4.14, p = 0.039) and ECOG (HR: 2.21, CI: 1.
21–4.04, p = 0.01) remained significant factors while M
stage (HR: 0.51, CI: 0.25–1.06, p = 0.07) did not reach
significance.
Discussion
In contrast to Asian lung adenocarcinoma patients,
there is relatively less information about the first-line
EGFR-TKI treatment response rates and progression-
free survival in Caucasian cohorts. Our non-randomized,
Fig. 1 EGFR mutation status in the screened population and best
response to first line erlotinib treatment. (a) Out of the 651 screened
patients, 62 carried EGFR mutations including 37 in exon 19 and 35
in exon 21. (b) The distribution of best response among the 56
intent-to-treat patients. (CR – complete remission, PR – partial
response, SD – stable disease, PD – progressive disease)
Markóczy et al. BMC Cancer  (2018) 18:598 Page 3 of 7
multicenter, phase IV clinical trial including first-line er-
lotinib treated lung adenocarcinoma patients with acti-
vating EGFR mutations was conducted for the very
reason. The ORR in our study is in accordance with
studies from East-Asia where RRs were found to be 70–
75% [13, 14]. Interestingly, the LUX-Lung 2 phase II trial
of the second-generation covalent TKI inhibitor afatinib
demonstrated similar RR in classic EGFR mutant
patients [15]. Of note, the 12.8-months median PFS in
our cohort is in the range of previously published data
(9.4–11.9 months) from other studies [14, 16].
Previously, three major randomised, phase III first-line
studies have shown a tendency for improved response to
erlotinib in patients with exon19 microdeletion-positive
tumors when compared to L858R-positive cases [6, 7, 17].
This tendency has not been observed in the current study,
however, the number of patients is limiting the identifica-
tion of smaller differences in the progression-free survival.
Of note, there was no difference at all in the smoking sta-
tus of patients in the exon 19 and exon 21 mutation
subgroup.
While smoking is clearly the most important factor in
the development of lung cancer, the prognostic and pre-
dicitve significance of smoking status is context
dependent. In several studies, never-smokers have im-
proved OS, however, the increased survival is at least in
part due to the overall better performance score and the
lack of smoking related comorbidities [18–21]. In stand-
ard chemotherapy regimens, predictive value of smoking
status is limited [19, 22, 23] or only slightly increased
survival can be demonstrated in never-smokers when
compared to smokers [24, 25]. In contrast, never-
smokers seem to have survival benefits in cohorts that
include EGFR-TKI treated patients [4]. Owing to the fact
that mutation of EGFR gene is more frequent in non-
smokers [26, 27], our study was biased towards never-
smokers. Of note, in the ever smoker group there are 4
patients out of 6 are censored beyond one-year that
might suggest a decreasing relative risk over time.
Nevertheless, there are only 20 patients in the ever
smoker subcohort including 3 current smokers. Thus
the size of the subcohort prevent us from studying the
time-dependent impact of smoking on the progression–
free survival. Nevertheless, we found a significantly im-
proved progression-free survival in never-smokers. One
reason might be the smoking induced additional muta-
tional load that can lead to the presence of tumor cell
clones with resistance mutations and thus lead to earlier
emergence of therapy resistance.
With regards to other clinicopathological parameters,
we found no significant difference between the gender-
Table 1 Clinicopathological characteristics of the 62 patients dichotomized by exon19 microdeletions and exon21 mutations
Total Exon19 Exon21 p-value
Number of patients 62 (100%) 37 (66.1%) 25 (33.9%)
Age (median, range) 70.5 (28–86) 67 (28–81) 71 (48–86) 0.088
Gender Male 12 (19.4%) 8 (21.6%) 4 (16%) 0.747
Female 50 (80.6%) 29 (78.4%) 21 (84%)
ECOG performance status 0 24 (38.7%) 17(46%) 7(28%) 0.182
1 32 (51.6%) 17(46%) 15(60%)
2 6(9.7%) 3(8%) 3 (12%)
Smoking status Never-smoker 42(67.7%) 25 (67.5%) 17 (68%) 1.00
Ever smoker 20(32.3%) 12 (32.5%) 8 (32%)
Tumor Stage IIIb 6 (9.7%) 1 (1.6%) 5(20%) 0.035
IV 56 (90.3%) 36(98.4%) 20(80%)
Data shown in parentheses are column percentages;
Table 2 Non-serious adverse events during erlotinib treatment
Adverse event Number of patients (%) Number of events
Rash 36 (58.1%) 43
Diarrhoea 17 (27.4%) 26
Dry skin 11 (17.7%) 15
Pruritus 9 (14.5%) 10
Asthenia 5 (8.1%) 9
Conjunctivitis 6 (9.7%) 8
Back pain 7 (11.3%) 8
Cough 8 (12.9%) 8
Alopecia 7 (11.3%) 7
Anaemia 5 (8.1%) 6
Growth of eyelashes 5 (8.1%) 5
Nausea 4 (6.5%) 5
Increased blood AP 5 (8.1%) 5
Weight loss 4 (6.5%) 5
Headache 5 (8.1%) 5
Dyspnoea 5 (8.1%) 5
Decreased appetite 4 (6.5%) 4
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specific PFS. However, the patient population in the
present study was biased towards female gender and
thus this analysis should be interpreted rather carefully
due to the low number (n = 12) of male patients in the
study.
In the present patient cohort ECOG PS was a sig-
nificant predictor of PFS. It is in line with a number
of other studies where better performance status
associated with improved anti-EGFR therapy re-
sponse [4, 28].
Other studies have previously demonstrated that dis-
seminated disease stage have an impact of progession-
free survival in EGFR-TKI treated patients [29]. In the
current study, there were only 6 non-metastatic pa-
tients included, thus the exploratory analysis of stage as
a predictor was limited to M1a and M1b subgroups. Of
Fig. 2 Kaplan-Meier analysis of progression-free survival. (a) The intent-to-treat cohort had a 12.8 months median PFS. (b) Never smoker
patients had increased progression-free survival. (c) Patients with extrathoracic metastasis at the time of screening had lower PFS than
patients with pulmonary metastasis. (d) ECOG2 patients demonstrated progression earlier when compared to ECOG1 or ECOG0
performance status
Table 3 Exploratory subgroup analysis of progression-free survival (n = 61)
N PFS (months) Ratio (CI) P HR (CI)
Gender Female 49 13.2 1.56 (1.101–2.023) 0.447 0.719 (0.305–1.696)
Male 12 8.45
Age ≤70 31 11.7 0.76 (0.225–1.294) 0.164 1.561 (0.834–2.922)
> 70 30 15.4
Smoking Never 41 15.4 0.545 (0.018–1.073) 0.045 2.118 (1.016–4.418)
Ever 20 8.4
Mutation Exon 19 37 13 0.79 (0.266–1.320) 0.607 1.186 (0.627–2.243)
Exon 21 24 16.4
ECOG 0 24 18.9 0.017
1 31 12.6
2 6 4.4
Stagea M1a 31 18.9 2.22 (1.708–2.739) 0.002 0.334 (0.167–0.672)
M1b 24 8.5
a6 IIIb stage patients were excluded from this analysis
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note, patients with metastasis limited to the lung and
pleural or pericardial effusion had a signficantly longer
PFS when compared to patients with distant organ
dissemination.
Conclusion
Overall, our phase IV clinical trial demonstrated that the
companion diagnostic method could identify lung
adenocarcinoma patients with activating EGFR mutation
with a frequency that was found in other Caucasian pa-
tient populations. Furthermore, it has been demostrated
that the first-line erlotinib treatment of this patient co-
hort had an efficacy and safety profile similar to previous
large randomized phase III clinical trials.
Abbreviations:
CI: confidence interval; CR: complete remission.; ECOG: PS Eastern Oncology
Cooperative Group performance status.; PD: progressive disease.;
PFS: Progression-free survival.; PR: partial response.; RR: response rate.;
SD: stable disease.
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